Early detection of disease, particularly cancer, is pivotal for improving patient outcomes. However, diagnostic approaches relying on traditional endogenous biomarkers often face significant limitations, primarily due to the low abundance and lack of specificity of these markers, which can lead to delayed or inaccurate diagnosis. Synthetic biomarkers, artificially engineered exogenous agents that are designed to interact with specific biological targets to generate detectable signals, represent a revolutionary approach in diagnostic medicine. By allowing for the conversion and amplification of specific disease-related signals, synthetic biomarkers enable accurate diagnosis, prognosis, and therapy monitoring, holding immense promise for the early detection of diverse disease states to facilitate prompt treatment initiation and to improve clinical outcomes. This review provides a comprehensive overview of the evolution, classification, working mechanisms, and diagnostic applications of synthetic biomarkers, along with a discussion of their future potential in advancing precision medicine and effective disease management.
No takes yet. Share an insight, caveat, or question.
An-yun et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: